Morgan Stanley Said to Revise Pharma Loan Deal Amid Valeant Rout

Updated on

Lannett Co. and its bank Morgan Stanley are sweetening terms on a $1.2 billion loan deal to lure investors stung by drug-maker debt following a selloff in Valeant Pharmaceuticals International Inc., according to people with knowledge of the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.